Disease/Infection News

RSS

New data confirms antiviral activity of fluvastatin in patients with HCV

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

DNA damage can lead to regulation of inflammatory responses

Researchers offer the first evidence that DNA damage can lead to the regulation of inflammatory responses, the body's reaction to injury. The proteins involved in the regulation help protect the body from infection.

1 Apr 2011

Study: Electronic faucets more likely to become contaminated with bacteria

Researchers at The Johns Hopkins University School of Medicine have determined that electronic faucets are more likely to become contaminated with unacceptably high levels of bacteria, including Legionella spp., compared with traditional manually operated faucets.

1 Apr 2011

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex Pharmaceuticals Incorporated today announced final results from its pivotal Phase 3 REALIZE study that evaluated people with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon and ribavirin was unsuccessful either because they relapsed, had a partial response or had a null response.

1 Apr 2011

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority announced today.

1 Apr 2011

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

A study of newly installed, hands-free faucets at The Johns Hopkins Hospital, all equipped with the latest electronic-eye sensors to automatically detect hands and dispense preset amounts of water, shows they were more likely to be contaminated with one of the most common and hazardous bacteria in hospitals compared to old-style fixtures with separate handles for hot and cold water.

1 Apr 2011

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a and ribavirin in a treatment experienced, hepatitis C virus null-responder patient population.

1 Apr 2011

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

1 Apr 2011

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex Pharmaceuticals Incorporated today announced interim results from an ongoing Phase 2 study designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease inhibitor, telaprevir, in combination with pegylated-interferon and ribavirin in people with genotype 1 chronic hepatitis C who were new to treatment.

31 Mar 2011

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Inhibitex, Inc. today reported positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus.

31 Mar 2011

South Sudan faces serious health challenges as new nation, Lancet Newsdesk reports

In South Sudan, which is poised to become "the world's newest country" in July, "90% of the population lives on less than $1 a day," and the region is plagued by multiple systemic health issues as a result of years of war, Lancet Infectious Diseases Newsdesk reports.

31 Mar 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

International experts gather in Prague today for a three day meeting focused on the impact of vaccines on public health, at a time of increasing concern that public scepticism and complacency could undermine the positive impact of current and future vaccine campaigns.

31 Mar 2011

EPA approves Clorox DISPATCH disinfectant towels registration to fight against C. difficile

The Clorox Company announced today that the U.S. Environmental Protection Agency approved the registration of DISPATCH Hospital Cleaner Disinfectant Towels with Bleach to kill Clostridium difficile spores in five minutes, the fastest C. difficile contact time available.

31 Mar 2011

Simple precautions can protect against zoonotic diseases

The risk of contracting zoonotic diseases that pass from animals to humans appears to be on the increase in the UK, but encouraging countryside users to take simple precautions to protect themselves is the best response, according to research undertaken by the UK research councils' Rural Economy and Land Use Programme.

31 Mar 2011

California State Controller calls upon Abbott, BI, BMS & Genentech to reduce AIDS drug prices for ADAPs

Today AIDS Healthcare Foundation (AHF) announced that California State Controller John Chiang has sent letters to the CEOs of Abbott, Boehringer Ingelheim (BI), Bristol-Myers Squibb (BMS) and Genentech, asking the companies to reduce the price of their HIV/AIDS medications for California and its AIDS Drug Assistance Program (ADAP).

31 Mar 2011

Boceprevir drug can help cure hard-to-treat hepatitis C

The drug boceprevir helps cure hard-to-treat hepatitis C, says Saint Louis University investigator Bruce R. Bacon, M.D., author of the March 31 New England Journal of Medicine article detailing the study's findings.

31 Mar 2011

Three-drug cocktail more effective against hepatitis C virus

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen, according to researchers at Henry Ford Hospital.

31 Mar 2011

HIV/AIDS drugs shortage with rise in cases: An update

According to Australia's Ambassador on HIV/AIDS, Murray Proctor, Asia is falling short on HIV/AIDS treatment as almost 400,000 new cases are reported each year. He was attending a regional conference on universal access to treatment for AIDS where he said availability and price of vital anti-retroviral or anti- HIV medications remain a challenge for the region.

31 Mar 2011

Disease/Infection News

New data confirms antiviral activity of fluvastatin in patients with HCV

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

DNA damage can lead to regulation of inflammatory responses

Study: Electronic faucets more likely to become contaminated with bacteria

Vertex announces final results from Phase 3 REALIZE study against HCV

Biota Scientific receives BARDA contract to develop single-dose antiviral drug

Hands-free electronic water faucets more likely to be contaminated with hazardous bacteria

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

South Sudan faces serious health challenges as new nation, Lancet Newsdesk reports

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

International experts meet to focus on impact of vaccines on global health at a time of public scepticism and complacency

EPA approves Clorox DISPATCH disinfectant towels registration to fight against C. difficile

Simple precautions can protect against zoonotic diseases

California State Controller calls upon Abbott, BI, BMS & Genentech to reduce AIDS drug prices for ADAPs

Boceprevir drug can help cure hard-to-treat hepatitis C

Three-drug cocktail more effective against hepatitis C virus

HIV/AIDS drugs shortage with rise in cases: An update

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Latest News